| Display title | Chemistry:Tesaglitazar |
| Default sort key | Tesaglitazar |
| Page length (in bytes) | 4,867 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 806545 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>LinuxGuru |
| Date of page creation | 02:19, 9 March 2024 |
| Latest editor | imported>LinuxGuru |
| Date of latest edit | 02:19, 9 March 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.
The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca announced that it had discontinued... |
